Business Description
CARISMA Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US14216R1014
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 7.54 | |||||
Equity-to-Asset | 0.15 | |||||
Debt-to-Equity | 0.69 | |||||
Debt-to-EBITDA | -0.09 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | -7.19 | |||||
Beneish M-Score | 0.93 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -54.6 | |||||
3-Year EPS without NRI Growth Rate | -54.3 | |||||
3-Year FCF Growth Rate | -53.3 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 20.72 | |||||
9-Day RSI | 25.41 | |||||
14-Day RSI | 27.94 | |||||
6-1 Month Momentum % | -38.91 | |||||
12-1 Month Momentum % | -76.16 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.64 | |||||
Quick Ratio | 4.64 | |||||
Cash Ratio | 4.3 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.3 | |||||
Shareholder Yield % | 43.53 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -565.71 | |||||
Net Margin % | -538.81 | |||||
FCF Margin % | -524.92 | |||||
ROE % | -171.7 | |||||
ROA % | -72.61 | |||||
ROIC % | -496.38 | |||||
ROC (Joel Greenblatt) % | -805.69 | |||||
ROCE % | -89.23 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 3.2 | |||||
PB Ratio | 4.54 | |||||
Price-to-Tangible-Book | 4.33 | |||||
EV-to-EBITDA | 0.03 | |||||
EV-to-Revenue | -0.09 | |||||
EV-to-Forward-Revenue | 0.03 | |||||
EV-to-FCF | -0.01 | |||||
FCF Yield % | -165.17 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
CARISMA Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 13.93 | ||
EPS (TTM) (€) | -1.812 | ||
Beta | 0 | ||
Volatility % | 123.37 | ||
14-Day RSI | 27.94 | ||
14-Day ATR (€) | 0.05819 | ||
20-Day SMA (€) | 1.2529 | ||
12-1 Month Momentum % | -76.16 | ||
52-Week Range (€) | 1.074 - 8.6 | ||
Shares Outstanding (Mil) | 41.54 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
CARISMA Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
CARISMA Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
CARISMA Therapeutics Inc Frequently Asked Questions
What is CARISMA Therapeutics Inc(FRA:W2J)'s stock price today?
When is next earnings date of CARISMA Therapeutics Inc(FRA:W2J)?
Does CARISMA Therapeutics Inc(FRA:W2J) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |